Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proven prostate cancer, locally advanced or metastatic and scheduled to receive hormonal deprivation therapy~* Life expectancy of more than 9 months~* Documented testosterone levels of ≥ 125 ng/dl measured by any laboratory or on site within the previous 6 months~Exclusion Criteria:~* Has a history of hypersensitivity to the Investigational Medicinal Product or drugs with a similar chemical structure~* Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen within the last year preceding the study~* Concomitant anti-coagulation treatment~* Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy during the course of this study~* Patient with known spinal medullar compression

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): triptorelin 11.25mg given 12 weekly by subcutaneous formulation
- 2 (Type: ACTIVE_COMPARATOR): triptorelin 11.25mg given 12 weekly by intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).